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Abstract The metabolic abnormalities of type 2 diabetes
can be reversed reproducibly by bariatric surgery. By
quantifying the major pathophysiological abnormalities in
insulin secretion and insulin action after surgery, the
sequence of events leading to restoration of normal
metabolism can be defined. Liver fat levels fall within days
and normal hepatic insulin sensitivity is restored. Simulta-
neously, plasma glucose levels return towards normal.
Insulin sensitivity of muscle remains abnormal, at least
over the weeks and months after bariatric surgery. The
effect of the surgery is explicable solely in terms of energy
restriction. By combining this information with prospective
observation of the changes immediately preceding the onset
of type 2 diabetes, a clear picture emerges. Insulin
resistance in muscle, caused by inherited and environmental
factors, facilitates the development of fatty liver during
positive energy balance. Once established, the increased
insulin secretion required to maintain plasma glucose levels
will further increase liver fat deposition. Fatty liver causes
resistance to insulin suppression of hepatic glucose output
as well as raised plasma triacylglycerol. Exposure of beta
cells to increased levels of fatty acids, derived from
circulating and locally deposited triacylglycerol, suppresses
glucose-mediated insulin secretion. This is reversible
initially, but eventually becomes permanent. The essential
time sequence of the pathogenesis of type 2 diabetes is now
evident. Muscle insulin resistance determines the rate at
which fatty liver progresses, and ectopic fat deposition in
liver and islet underlies the related dynamic defects of
hepatic insulin resistance and beta cell dysfunction. These
defects are capable of dramatic reversal under hypoener-
getic feeding conditions, completely in early diabetes and to
a worthwhile extent in more established disease.
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Introduction
Puzzles are often most easily solved backwards. Isaac Newton
exemplified this by using his newly invented and secret tool of
calculus to establish the answer to unsolved mathematical
problems, then presenting the proof in conventional mathe-
matical terms having worked backwards to the question [1].
The same technique can be applied to unravelling the
pathogenesis of disease, but there is a snag—a cure for the
disease has to be discovered so that the pathogenesis may be
observed, step by step, in reverse. However, it is now
possible to achieve a cure in groups of people with type 2
diabetes. What happens during the period of return to normal
insulin sensitivity and normal beta cell function?
Bariatric surgery and type 2 diabetes
The acid test for any new treatment is a prospective,
randomised comparison with conventional treatment. Dixon
and colleagues randomised patients with a BMI of 30–
40 kg/m2 and type 2 diabetes duration of <2 years to a
conventional treatment group or a surgically treated group
[2]. The conventional group was treated using intensive
lifestyle modification programmes, dietary advice, oral
hypoglycaemic agents and insulin, and was followed up
every 6 weeks. The surgically treated group underwent
laparoscopic placement of an adjustable gastric band in
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addition to receiving the conventional treatment. The
primary endpoint was remission of diabetes, defined as an
HbA1c level of <6.2% and a fasting plasma glucose level of
<7.0 mmol/l, off all treatment. At 2 years, remission was
achieved in 13% of the conventional treatment group and
73% of the surgical group. Fasting plasma glucose fell from
the baseline level of 8.8 mmol/l to 7.7 mmol/l in the
conventional treatment group and to 5.9 mmol/l in the
surgically treated group (Fig. 1). This was associated with
weight change from 106 kg at baseline to 105 kg and 85 kg
in the two groups, respectively (Fig. 1). The importance of
the study lies in the demonstration, in a prospective,
randomised setting, that normalisation of plasma glucose
can be achieved in groups of individuals. Diabetologists
have long known that the tiny proportion of iron-willed
people who can substantially decrease their weight and
maintain this, can exhibit a return to normal metabolism.
Dixon and colleagues have demonstrated a more widely
applicable phenomenon.
However, gastric banding is the least dramatic of possible
surgical procedures to achieve weight loss. It involves the
placement of an adjustable cuff around the gastro-oesophageal
junction, and may be done via a laparoscope. At the other
end of the scale, bilio-pancreatic diversion consists of distal
gastric resection with closure of duodenal stump, trans-
section of the small intestine, proximal anastomosis to
stomach and anastomosis of the remaining ileum (carrying
bilio-pancreatic secretions) to the distal ileum. Simple gastric
bypass involves ileo-gastric anastomosis so that food bypasses
the duodenum and upper jejunum. An earlier systematic review
indicated resolution of diabetes in 99% after bilio-pancreatic
diversion, 84% for gastric bypass and 48% for gastric banding
[3]. Gastric bypass surgery, with its attendant risks, has been
known for 20 years to bring about major weight loss and
improve glucose tolerance in morbidly obese individuals. In
the original series by Pories et al., 86 of 88 obese people with
diabetes reverted to normal glucose tolerance within 4 months,
and this remained normal over 6 years of follow-up [4].
Time-course of reversal of pathogenic factors
Recently, several detailed studies of metabolic changes
following gastric bypass surgery have thrown further light
upon reversal of type 2 diabetes. A prospective study of ten
obese patients with type 2 diabetes undergoing bilio-pancreatic
diversion, with re-study after 2 years, demonstrated weight
change from 136 to 89 kg [5]. This was accompanied by a fall
in the fasting plasma glucose level from 7.7 to 5.1 mmol/l and
a decrease in the HbA1c level from 8.2% to 4.1%. The
improvement in insulin sensitivity measured during a
euglycaemic–hyperinsulinaemic clamp was not surprising in
the context of the weight loss (the glucose disposal rate per
kg of fat-free mass rose from 26.4 to 55.2 μmol min−1; it was
68.7 μmol min−1 in a non-diabetic post-bypass group).
However, the return of beta cell sensitivity for insulin
secretion in the type 2 diabetic patients (from 44 to 76 pmol
min−1 m−2 [mmol/l]−1) to levels above those seen in the non-
diabetic post-bypass control group (65 pmol min−1 m−2
[mmol/l]−1) was striking. The term ‘inexorable decline’ is
traditionally applied to beta cell function in established type 2
diabetes. The recent data clearly demonstrate that this is not
necessarily the case, at least in the first few years after
diagnosis. What could underlie this reversal of the twin
pathogenic factors of type 2 diabetes?
Insight into the time-course of change following a gastric
bypass has been gained from detailed studies conducted
over the first 4 weeks after surgery [6]. A group of morbidly
obese people with a diabetes duration of between 1 and
3 years were studied. Preoperatively, the fasting blood
glucose level was 7.8 mmol/l and, as would be expected,
both beta cell sensitivity to glucose and whole body insulin
sensitivity were low. After pancreatobiliary diversion, the
group were re-studied at 1 and 4 weeks. Parenteral feeding
provided 7.5 MJ/day (1,800 kcal/day) for the first six
postoperative days, but this would represent a sudden
decrease in energy consumption. As body weight was
152 kg preoperatively, a daily intake of about 13.4 MJ/day
(3,200 kcal/day) would be required for weight maintenance
[7]. By 7 days postoperatively, fat mass had decreased by
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Fig. 1 Effect of intensive conventional therapy (blue lines) or gastric
banding (red lines) on body weight (a), fasting plasma glucose (b),
plasma triacylglycerol (c) and requirement for insulin or oral
hypoglycaemic agents (d). In the gastric banding group, fasting
plasma glucose and triacylglycerol returned to levels within the
normal range. Data represent means (n=30 for each group) and are
replotted from reference [2] with permission
1782 Diabetologia (2008) 51:1781–1789
4.4 kg and the fasting blood glucose level had fallen to
5.9 mmol/l (Fig. 2). Insulin sensitivity, measured as the
glucose infusion rate during euglycaemic–hyperinsulinaemic
clamps, had doubled. Correspondingly, the fasting plasma
insulin level had fallen from 136 to 108 pmol/l. By 4 weeks
postoperatively, the fasting plasma glucose level had fallen
further (to 4.8 mmol/l), with no further change in insulin
sensitivity. The observed change in insulin sensitivity
requires careful consideration.
The euglycaemic–hyperinsulinaemic clamp is usually
assumed to reflect muscle insulin sensitivity [8]. This is
because elevations in plasma insulin levels rapidly bring
about complete suppression of glucose production by the
liver. Under these circumstances, the rate at which glucose
is infused directly reflects the rate at which muscle tissue is
stimulated to take up glucose. However, it has been known
for some time that glucose production by the liver is not
completely suppressed during the clamp in obese individ-
uals [9]. Thus, this method underestimates glucose uptake
by muscle, because the continuing production of glucose by
the liver is ignored. The relevance of this for understanding
pathogenesis has been elegantly demonstrated by Petersen
and colleagues [10]. Figure 3 shows that the marked
increase in glucose requirements during euglycaemic hyper-
insulinaemia is almost entirely explained by greater
suppression of liver glucose production, and that the total
uptake of glucose by muscle is essentially unchanged. This
figure also illustrates that the change in liver response to
insulin represents a remarkable normalisation of insulin
suppression of glucose production by the liver. This
observation focuses attention upon the early changes in
the liver during the onset of energy restriction.
The changes in liver volume and liver fat content during
a period of very low energy intake have been examined
[11]. The study was undertaken to define the rate of change
of liver volume. This is important as a reduction in liver
size before bariatric surgery makes the procedure easier to
perform and considerably decreases the complication rate.
Over a 12 week period, during which participants ingested
1.88–2.85 MJ/day (450–680 kcal/day), liver volume de-
creased by 30%. However, 80% of the change occurred
during the first 2 weeks. During weight loss there is a tight
relationship between liver volume and liver fat content [12],
and it appeared that intra-hepatic fat was mobilised more
rapidly than visceral or subcutaneous fat. This suggestion
that liver fat stores are called upon first at the onset of
negative energy balance has been examined directly by two
studies using magnetic resonance methodology.
Petersen and colleagues observed that a loss of 8% of
body weight over 7 weeks was associated with an 81%
decrease in hepatic fat [10]. It is clear that liver fat is
mobilised within days of onset of hypoenergetic feeding.
Hollingsworth and colleagues observed the changes that
accompanied weight loss of 3 kg over the first 10 days of a
low-energy diet [13]. Liver fat fell significantly from 9.4±
1.8% at baseline to 8.2±1.1% at 3 days and 7.0±1.3 at
10 days (normal liver fat content <5%), demonstrating that
very early substantial mobilisation of this fat depot occurs
during dietary restriction.
Overall, this early and major decrease in liver fat occurs
at the same time as normalisation of hepatic insulin
sensitivity and a fall in fasting blood glucose level. This
is entirely as would be expected from knowledge of the
relationship between the extent of hepatic steatosis and
suppression of hepatic glucose production by insulin [14,
15]. The reason for the rapid return of beta cell sensitivity
to glucose is less certain. Even in normal individuals,
insulin secretion can be blunted by constant hyperglycae-
mia [16], and the removal of ‘glucotoxicity’ could be a
partial explanation. In addition, it is known that fat
accumulation in and around the pancreatic islets is directly
associated with impaired beta cell function in humans [17].
In obese rodents, the onset of hyperglycaemia is preceded by
a rapid increase in pancreatic fat [18], and the mechanism of
impairment of insulin secretion during chronic exposure of
islet beta cells to fatty acids has been shown to be marked
0 1 2 3 4
2
4
6
8
10
G
lu
c
o
s
e
(m
m
o
l/
l)
0 1 2 3 4
0
50
100
150
200
In
s
u
lin
(p
m
o
l/l
)
0 1 2 3 4
20
40
60
80
In
s
u
lin
 s
e
n
s
it
iv
it
y
(µ
m
o
l 
[k
g
 F
F
M
]–
1
 m
in
–
1
)
Time (weeks) Time (weeks) Time (weeks)
a b c
Fig. 2 Change in fasting plasma glucose (a), fasting plasma insulin
(b) and insulin sensitivity (c) over the 4 weeks after bilio-pancreatic
diversion in morbidly obese individuals with type 2 diabetes. The
changes in plasma glucose and insulin sensitivity during the first week
are striking. The yellow areas represent normal ranges. FFM, fat-free
mass. Data represent mean±SE (n=10) and are replotted from
reference [6] with permission
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suppression of pyruvate cycling, which normally occurs
during hyperglycaemia [19]. It is possible that such ectopic
fat around the islets could be mobilised with the same
dynamics as intra-hepatic fat, and that the early phase of
fasting relieves the beta cells of the inhibitory burden of
locally released fatty acids and diacylglycerol.
Fois gras in man and beast
Obesity is strongly related to non-alcoholic fatty liver
disease [20]. This is true in early life as well as in
adulthood. An autopsy study has demonstrated a dose
relationship between the degree to which children are
overweight and the presence of fatty liver [21]. In
adolescence, 30% of obese individuals have fatty liver
[22] and the extent of liver fat accumulation is inversely
proportional to habitual daily physical activity, both in type
2 diabetic and non-diabetic individuals [23]. But which
comes first? Are individuals with fatty liver more prone to
insulin resistance and weight gain, or do lifestyle factors
initiate and underlie fatty liver?
Farmers are the supreme experts at the practical
manipulation of nature. The production of fatty liver in
ducks and geese has been honed over at least 2,500 years
[24]. Currently, the birds are allowed increasing access to
high-carbohydrate feed over a 12 week free-range period.
During this phase, rapid weight gain occurs and the livers
become fatty, enlarging to 50% of their final size. This is
equivalent to severe fatty liver for man. In the final 12 days,
gavage is used to administer a large, high-fat energy
overload and exacerbate the hepatic fat excess. However,
the first phase of fois gras production gives all the
necessary clues to the genesis of fatty liver in man.
Prolonged intake of energy in excess of requirement will
bring about intra-hepatic triacylglycerol deposition.
The effect of modifying plasma insulin levels on fatty
liver
As the predominant anabolic hormone of metabolism,
insulin plays a major role in promoting the synthesis and
storage of fatty acid/triacylglycerol. Under conditions of
constant hyperinsulinaemia and a modest elevation of the
plasma glucose level, fatty acid synthesis from glucose is
accelerated [25]. The extent of portal hyperinsulinaemia
will determine how much glucose is converted into fatty
acid in the liver. This process will be significant when the
24 h energy intake exceeds expenditure over the same
period [26, 27]. In groups of obese individuals, those with a
higher plasma insulin level have markedly increased rates
of de novo lipogenesis [26]. Newly synthesised triacylgly-
cerol in the liver can be either oxidised, exported as VLDL
or stored as hepatic triacylglycerol. As transport of fatty
acid into mitochondria for oxidation is inhibited by
malonyl-CoA, which is produced during lipogenesis [28],
newly synthesised triacylglycerol is preferentially directed
towards storage or export, thus increasing hepatic fat
content and/or increasing the concentration of plasma
VLDL triacylglycerol. From this biochemical perspective,
increased insulin secretion in the presence of positive
energy balance can explain the initiation of fatty liver.
The process will be hastened in the presence of peripheral
insulin resistance and hence higher plasma insulin levels.
The implication that the fatty liver in type 2 diabetes is
not secondary to hyperglycaemia but is determined by
portal hyperinsulinaemia can neatly be tested by examining
the extent of fatty liver in type 1 diabetes. In this condition,
hyperglycaemia coexists with portal insulin concentrations
that are approximately 2.5-fold lower than normal, as there
is no portal/peripheral gradient. Liver fat content in a group
of 19 individuals with type 1 diabetes was reported to be
one-third lower than that in matched controls [29]. This
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Fig. 3 Physiological changes during 8% weight loss in obese
individuals with type 2 diabetes compared with matched controls.
The improvement in insulin sensitivity during the euglycaemic–
hyperinsulinaemic clamp (a) would conventionally be interpreted as
an improvement in the insulin sensitivity of muscle. However,
determination of muscle glucose uptake during the clamps demon-
strates no significant change (b), in sharp contrast to the simultaneous
normalisation of the suppression of hepatic glucose production (c).
The early improvement in glucose homeostasis during weight loss is
associated with changes in the hepatic rather than peripheral tissue
response to insulin. HGP, hepatic glucose production; LBM, lean body
mass; T2D, type 2 diabetes. Data represent mean±SE (n=8) and are
replotted from reference [10] with permission
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indicates that when the portal insulin concentration is low,
liver fat content is low.
It is therefore important to examine the effect of
decreasing insulin secretion. This may be achieved in four
ways. First, hypoenergetic diets lead to lower insulin
secretion rates, but in the context of negative energy balance
it is not remarkable that liver fat content falls [30]. Second,
increased physical activity increases muscle insulin sensi-
tivity and decreases the plasma insulin level. The extent of
habitual daily physical activity has been shown to be
negatively correlated with the degree of hepatic steatosis,
both in type 2 diabetic and non-diabetic groups [23], and
this effect is additive to advice on weight loss [31]. Third,
thiazolidinediones increase insulin sensitivity and decrease
insulin secretion rates. These agents bring about a 54%
decrease in liver fat content [32, 33]. Finally, use of
subcutaneous insulin in type 2 diabetes brings about
decreases in portal insulin delivery and liver fat [34].
Taken together, the biochemical and clinical trial informa-
tion points to endogenously secreted insulin as the major
promoter of hepatic steatosis. There is no reason to believe
that hyperglycaemia per se promotes fat deposition in the
liver, although its secondary effect will play a role in impaired
glucose tolerance and early type 2 diabetes via increased
insulin secretion rates and, hence, increased liver fat.
Assembling the time-course to type 2 diabetes
It has long been known that subnormal insulin sensitivity is
the best predictor of the risk of developing type 2 diabetes.
Recent studies have emphasised the primacy of extrahepatic
insulin resistance [35]. In such individuals, raised plasma
insulin levels compensate in terms of plasma glucose
control, but set the scene for enhanced lipogenesis in the
liver. The best available information suggests that excess fat
deposition in the liver is uniformly present before the onset
of classical type 2 diabetes [22, 23, 36–39]. Liver fat content
is supra-normal in type 2 diabetes, with minimal crossover of
range with normal individuals [23]. Such studies using
magnetic resonance spectroscopy are able to quantify liver
fat precisely, as are biopsy studies. A necessarily small
biopsy series has shown all of a group of ten type 2 diabetic
volunteers to have hepatic steatosis [40]. When ultrasound is
used, only more severe degrees of steatosis are detected, and
the prevalence of fatty liver will be underestimated. A large
ultrasound-based study has shown 70% of people with type
2 diabetes to have fatty liver [39]. Nonetheless, even using
ultrasound to classify individuals at baseline as either having
or not having fatty liver, the prognostic power of predicting
onset of type 2 diabetes within 8 years is impressive (Fig. 4)
[36]. This study of 3,189 individuals with normal glucose
tolerance at baseline showed a very low incidence of type 2
diabetes over 8 years if fatty liver had been excluded at
baseline. Even when adjusted for age and BMI, the hazard
ratio for diabetes was 5.5 (range 3.6–8.5).
In support of this, Suzuki demonstrated a temporal
progression from weight gain to raised levels of liver
enzymes, to hypertriglyceridaemia and, eventually, glucose
intolerance [41]. It must be noted that the association of
raised liver enzyme concentrations with fatty liver is strong
between groups with and without type 2 diabetes but not
absolute for diabetic individuals, who may exhibit an
increase within the normal range. In a group of 84 children
with biopsy-confirmed non-alcoholic fatty liver disease,
most were insulin resistant and 12% already had abnormal
glucose tolerance [42]. Certainly, weight loss can slow or
halt the pathogenesis of type 2 diabetes. When a group of
individuals with impaired glucose tolerance was followed
over time, weight loss of only 1 kg decreased the incidence
of diabetes by 20% [43].
The clearest prospective information of the time course
to development of type 2 diabetes comes from the West of
Scotland Coronary Prevention Study [38]. In a large group
of men followed for 2 years, 9% developed diabetes during
the period of observation. Two years before the onset of
type 2 diabetes, this subgroup was characterised by having
elevated levels of plasma triacylglycerol and alanine
aminotransferase (Fig. 5). There was a steady rise in the
level of this liver enzyme in the run-up to the time of
diagnosis, suggesting that the burden on the liver cells was
steadily increasing. In contrast, although fasting plasma
glucose concentration was marginally above that of the group
who did not develop diabetes, it remained fairly constant until
the fewmonths immediately prior to the diagnosis of diabetes,
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Fig. 4 Cumulative incidence of new-onset diabetes in men with
previously normal glucose tolerance. At baseline, liver fat content was
assessed by ultrasound, and the fatty liver group (red line) and non-
fatty liver group (blue line) were prospectively followed. If fatty liver
was not present at baseline, the risk of developing type 2 diabetes was
very low, even though the method used for detection of fatty liver has
low sensitivity and some individuals with fatty liver would have been
included in the non-fatty liver group (log-rank test p<0.001 for
difference between the groups). Data are 6 monthly cumulative
incidence rates for 3,135 and 9,744 person-years of follow-up for
the fatty liver and non-fatty liver groups, respectively. Figure replotted
from reference [36] with permission
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when a rapid rise occurred. There was not a gradual
decompensation with a linear increase in fasting plasma
glucose, as is often assumed. In established type 2 diabetes,
hepatic glucose production in everyday life remains relatively
unsuppressed [44] and postprandial plasma insulin levels are
elevated by approximately 2.5-fold [45].
The difference in the time-course of change in patho-
genic factors during the natural history of type 2 diabetes
and during its reversal by bariatric surgery deserves
comment (see text box: Steps in the pathogenesis of type
2 diabetes). Fatty liver becomes established years before the
onset of type 2 diabetes. It appears necessary but not
sufficient for its development. The subsequent period of
years of over-exposure of the islets to an elevated plasma
triacylglycerol level and a modest increase in the plasma
glucose level is necessary to precipitate beta cell decom-
pensation. Individuals are likely to exhibit different degrees
of islet sensitivity in response to the adverse effects of these
factors. However, in established diabetes, sudden mobilisa-
tion of the liver fat allows normal physiology to be
reinstated within days, provided that long-term damage to
the beta cells has not yet occurred. The published data
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Fig. 5 Changes observed during follow-up in the West of Scotland
Coronary Prevention Study. Individuals who developed type 2
diabetes (red lines) during the study were compared with those who
remained normoglycaemic (blue lines). It can be seen that they were
characterised as having raised plasma glucose levels for at least
2 years (a). Over this period, plasma alanine aminotransferase (ALT)
steadily rose (b). A relatively sudden increase in plasma glucose then
occurred. Triacylglycerol levels were elevated but relatively constant
from at least 2 years before diagnosis (c). Data replotted from
reference [38] with permission
Steps in the pathogenesis of type 2 diabetes
Approximate time scale 
Reverse pathogenesis 
• Negative energy balance 
• Decrease of liver fat Days 
• Increase in insulin suppression of liver glucose
production 
Days 
• Improvement of glucose-stimulated insulin 
secretion 
Days 
• Decrease in plasma glucose Days to weeks 
• Decrease in plasma triacylglycerol Days to weeks 
Natural history 
• Positive energy balance 
• Accelerated progression of insulin resistance Lifelong or years 
• Increased liver fat Years 
• Increased plasma triacylglycerol Years 
• Unrestrained liver glucose production Few years 
• Initial elevation of plasma glucose Few years 
• Excess exposure of islets to fatty acid Months to years 
• Decreased insulin secretion in response to 
glucose 
Months to years 
• Hyperglycaemia Months 
• Irreversible beta cell loss and dysfunction >2 years 
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suggest that 2–3 years of type 2 diabetes does not usually
produce irreversible beta cell damage.
By assimilating the knowledge gained from studies of
the reversal of type 2 diabetes into the prospective
observation of the development of the condition a clear
temporal pattern, the twin cycle hypothesis, can be
described (Fig. 6). Energy imbalance allows the onset of
fatty liver. Peripheral insulin resistance, either as a familial
trait or as a result of lifestyle factors, will expedite this
process because of hyperinsulinaemia. The increased liver
fat brings about a degree of hepatic insulin resistance that
involves failure to suppress fasting glucose production. The
degree of hepatic steatosis will be exacerbated by the portal
hyperinsulinaemia, and a raised plasma triacylglycerol
level signals the presence of excess liver fat [46]. Exposure
of the beta cells to excess fatty acids derived from circu-
lating and locally deposited triacylglycerol suppresses
glucose-mediated insulin secretion [17–19].
The twin vicious cycles then grind onwards. Raised
intrahepatic triacylglycerol leads to decreased suppression
of hepatic glucose output, which increases basal insulin
secretion and further increases intrahepatic triacylglycerol.
Separately but sequentially, supra-normal plasma glucose
and fatty acid delivery causes decreased postprandial beta
cell function and decreased glucose-responsive insulin
secretion, leading to further excursions in plasma glucose.
At a threshold determined by individual factors, beta cell
decompensation occurs and the plasma glucose level rises
relatively rapidly, leading to biochemical or symptomatic
presentation of type 2 diabetes. Over several years of
diabetes, the cumulative effects of excessive glucose and
fatty acid exposure bring about a degree of impairment of
beta cell function that is irreversible. There is continued
decline for as long as the causative factors of energy
overload and raised liver fat persist. At some point, insulin
therapy is required for reasonable control of plasma
glucose.
Conclusions
The essential time sequence of the pathogenesis of type 2
diabetes is now evident. Muscle insulin resistance deter-
mines the rate at which fatty liver progresses, and ectopic
fat deposition in the liver and islets underlies the related
dynamic defects of hepatic insulin resistance and beta cell
dysfunction. These defects are capable of dramatic reversal
under hypoenergetic feeding conditions, completely in early
diabetes and to a worthwhile extent in more established
disease.
It is now clear that we are dealing with an ecological
phenomenon, the aetiology of which demonstrably lies in
positive energy balance. Nowhere is this more clearly
illustrated than in the Pima Indians, a population in which
the prevalence of type 2 diabetes has risen from 0% to 40%
over half a century, in step with a change from subsistence
farming to inactivity and surplus food [47]. When our
species finds itself living under conditions of exercise
dearth and energy excess, the mechanisms that evolved
over millennia to allow populations to withstand famines
become maladaptive.
Two important questions emerge: Does the species have
the ability to adjust its environment and avoid the primary
causes of type 2 diabetes? What distinguishes those
individuals who appear resistant to the metabolic challenge,
remaining normoglycaemic in the face of little exercise and
much eating?
Positive calorie balance
Liver fat
Basal insulin secretion
Resistance to insulin 
suppression of HGP
Plasma glucose
VLDL triacylglycerol
Islet triacylglycerol
Insulin response to 
ingested glucose
Cycle A
Cycle B
Pre-existing insulin resistance+ +
Fig. 6 The twin vicious cycles of type 2 diabetes. During the chronic
intake of more energy than is expended each day, fat will accumulate
in the liver. As this process is promoted by insulin, individuals with a
degree of insulin resistance (determined by family or lifestyle factors)
will accumulate liver fat more readily than others. As the liver fat
increases, the process of glucose production by the liver becomes less
sensitive to suppression by insulin, plasma glucose tends to rise and
basal insulin secretion rates rise. This forms vicious cycle A (in blue).
The increased liver fat will increase secretion of triacylglycerol from
the liver. All tissues will be exposed to more triacylglycerol than
required, but the pancreatic islets are susceptible to local triacylgly-
cerol accumulation. The red arrows represent proximal steps to the
onset of type 2 diabetes. The post-meal response to glucose becomes
blunted, and this is exacerbated by the modestly raised plasma
glucose. Vicious cycle B (in red) causes impaired glucose regulation,
and eventually the fatty acid and glucose inhibitory effects on the
islets reach a threshold, leading to a relatively sudden onset of clinical
diabetes. Other processes may contribute to beta cell dysfunction in
addition to the fatty acid effect, contributing to the heterogeneity in
clinical phenotype
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